{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:01:48Z","timestamp":1781053308508,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015627","name":"Quest Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015627","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Monogram Biosciences"},{"name":"Orasure Technologies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01445-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:17:33Z","timestamp":1776766653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Substance use and mental health before versus during COVID-19 pandemic among persons who inject drugs with HCV infection history\u2014the HERO study"],"prefix":"10.1186","volume":"23","author":[{"given":"Snehal S.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pericot-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna L.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Murray-Krezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Karasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Arnsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Moschella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonseong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"4","key":"1445_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1515\/dx-2021-0046","volume":"8","author":"PJ Chen","year":"2021","unstructured":"Chen PJ, Pusica Y, Sohaei D, Prassas I, Diamandis EP. An overview of mental health during the COVID-19 pandemic. Diagnosis. 2021;8(4):403\u201312.","journal-title":"Diagnosis"},{"key":"1445_CR2","doi-asserted-by":"crossref","unstructured":"Avena N, Simkus J, Lewandowski A, Gold M, Potenza M. Substance use disorders and behavioral addictions during the COVID-19 pandemic and COVID-19-related restrictions. Volume 12. FRONTIERS IN PSYCHIATRY; 2021.","DOI":"10.3389\/fpsyt.2021.653674"},{"issue":"6","key":"1445_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/phn.12959","volume":"38","author":"H Green","year":"2021","unstructured":"Green H, Fernandez R, MacPhail C. The social determinants of health and health outcomes among adults during the COVID-19 pandemic: a systematic review. Public Health Nurs. 2021;38(6):942\u201352.","journal-title":"Public Health Nurs"},{"key":"1445_CR4","doi-asserted-by":"crossref","unstructured":"Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. PHARMACEUTICALS. 2020;13(7).","DOI":"10.3390\/ph13070155"},{"issue":"1","key":"1445_CR5","first-page":"17","volume":"33","author":"E Mellos","year":"2022","unstructured":"Mellos E, Paparrigopoulos T. Substance use during the COVID-19 pandemic: what is really happening? Psychiatrike = Psychiatriki. 2022;33(1):17\u201320.","journal-title":"Psychiatrike = Psychiatriki"},{"issue":"9","key":"1445_CR6","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.3390\/ijerph19095351","volume":"19","author":"LD Williams","year":"2022","unstructured":"Williams LD, Lee E, Latkin C, Mackesy-Amiti ME, Kaufmann M, Copulsky E, et al. Economic challenges and behavioral and mental health risks for overdose during the COVID-19 pandemic among people who inject drugs. Int J Environ Res Public Health. 2022;19(9):5351.","journal-title":"Int J Environ Res Public Health"},{"key":"1445_CR7","doi-asserted-by":"crossref","unstructured":"Aponte-Melendez Y, Mateu-Gelabert P, Fong C, Eckhardt B, Kapadia S, Marks K. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm Reduct J. 2021;18(1).","DOI":"10.1186\/s12954-021-00568-3"},{"key":"1445_CR8","doi-asserted-by":"crossref","unstructured":"Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: a rapid phone survey in Baltimore, Maryland. Drug Alcohol Depend. 2021;221.","DOI":"10.1016\/j.drugalcdep.2021.108584"},{"issue":"1","key":"1445_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12954-023-00746-5","volume":"20","author":"ST Allen","year":"2023","unstructured":"Allen ST, Schneider KE, Morris M, Rouhani S, Harris SJ, Saloner B, et al. Factors associated with receptive injection equipment sharing among people who inject drugs: findings from a multistate study at the start of the COVID-19 pandemic. Harm Reduct J. 2023;20(1):18.","journal-title":"Harm Reduct J"},{"key":"1445_CR10","doi-asserted-by":"crossref","unstructured":"Litwin A, Jost J, Wagner K, Heo M, Karasz A, Feinberg J et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: the HERO study. Contemp Clin Trials. 2019;87.","DOI":"10.1016\/j.cct.2019.105859"},{"issue":"12","key":"1445_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","volume":"7","author":"AH Litwin","year":"2022","unstructured":"Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, et al. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1445_CR12","doi-asserted-by":"publisher","first-page":"104288","DOI":"10.1016\/j.drugpo.2023.104288","volume":"123","author":"SS Lopes","year":"2023","unstructured":"Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, et al. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study. Int J Drug Policy. 2023;123:104288.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1445_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","volume":"31","author":"KA Bradley","year":"2007","unstructured":"Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcoholism: clin Experimental Res. 2007;31(7):1208\u201317.","journal-title":"Alcoholism: Clin Experimental Res"},{"issue":"2","key":"1445_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.drugalcdep.2004.04.018","volume":"76","author":"D Calsyn","year":"2004","unstructured":"Calsyn D, Saxon A, Bush K, Howell D, Baer J, Sloan K, et al. The addiction severity index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug Alcohol Depend. 2004;76(2):165\u201371.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"1445_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1445_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"R Spitzer","year":"2006","unstructured":"Spitzer R, Kroenke K, Williams J, Lowe B. A brief measure for assessing generalized anxiety disorder - The GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1445_CR17","doi-asserted-by":"publisher","first-page":"e2036462","DOI":"10.1001\/jamanetworkopen.2020.36462","volume":"4","author":"M Karmakar","year":"2021","unstructured":"Karmakar M, Lantz PM, Tipirneni R. Association of social and demographic factors with COVID-19 incidence and death rates in the US. JAMA Netw open. 2021;4(1):e2036462.","journal-title":"JAMA Netw open"},{"issue":"2","key":"1445_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s41666-021-00093-9","volume":"5","author":"Y Shao","year":"2021","unstructured":"Shao Y, Ahmed A, Liappis AP, Faselis C, Nelson SJ, Zeng-Treitler Q. Understanding demographic risk factors for adverse outcomes in COVID-19 patients: explanation of a deep learning model. J Healthc Inf Res. 2021;5(2):181\u2013200.","journal-title":"J Healthc Inf Res"},{"key":"1445_CR19","doi-asserted-by":"publisher","first-page":"107289","DOI":"10.1016\/j.ypmed.2022.107289","volume":"164","author":"D Park","year":"2022","unstructured":"Park D, Oh S, Cano M, Salas-Wright CP, Vaughn MG. Trends and distinct profiles of persons who inject drugs in the United States, 2015\u20132019. Prev Med. 2022;164:107289.","journal-title":"Prev Med"},{"key":"1445_CR20","doi-asserted-by":"crossref","unstructured":"Bolinski RS, Walters S, Salisbury-Afshar E, Ouellet LJ, Jenkins WD, Almirol E et al. The impact of the COVID-19 pandemic on drug use behaviors, fentanyl exposure, and harm reduction service support among people who use drugs in rural settings. Int J Environ Res Public Health. 2022;19(4).","DOI":"10.3390\/ijerph19042230"},{"issue":"2","key":"1445_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/wps.20995","volume":"21","author":"ND Volkow","year":"2022","unstructured":"Volkow ND, Maua S, Campello G, Poznyak V, Krupchanka D, Kashino W, et al. Prevention, treatment and care of substance use disorders in times of COVID-19. World Psychiatry. 2022;21(2):323\u20134.","journal-title":"World Psychiatry"},{"issue":"4","key":"1445_CR22","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.15190\/d.2021.20","volume":"9","author":"NC Chacon","year":"2021","unstructured":"Chacon NC, Walia N, Allen A, Sciancalepore A, Tiong J, Quick R, et al. Substance use during COVID-19 pandemic: impact on the underserved communities. Discoveries. 2021;9(4):e141.","journal-title":"Discoveries"},{"key":"1445_CR23","doi-asserted-by":"crossref","unstructured":"Bartholomew T, Nakamura N, Metsch L, Tookes H. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Volume 83. INTERNATIONAL JOURNAL OF DRUG POLICY; 2020.","DOI":"10.1016\/j.drugpo.2020.102821"},{"issue":"6","key":"1445_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/15589447221077377","volume":"18","author":"Y Sardiwalla","year":"2023","unstructured":"Sardiwalla Y, Nachmani O, Price E, Huynh M, Coroneos C, McRae M. Upper extremity infection related to intravenous drug use: considering the true cost of the COVID-19 pandemic and lockdown. Hand (N Y). 2023;18(6):999\u20131004.","journal-title":"Hand (N Y)"},{"issue":"1","key":"1445_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/rapm-2022-103591","volume":"48","author":"S Simha","year":"2023","unstructured":"Simha S, Ahmed Y, Brummett CM, Waljee JF, Englesbe MJ, Bicket MC. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review. Reg Anesth Pain Med. 2023;48(1):37\u201343.","journal-title":"Reg Anesth Pain Med"},{"issue":"S1","key":"1445_CR26","first-page":"S","volume":"24","author":"JK Niles","year":"2021","unstructured":"Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul health Manage. 2021;24(S1):S\u201343. 51.","journal-title":"Popul health Manage"},{"issue":"5","key":"1445_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","volume":"41","author":"C Kibaly","year":"2021","unstructured":"Kibaly C, Alderete JA, Liu SH, Nasef HS, Law P-Y, Evans CJ, et al. Oxycodone in the opioid epidemic: high \u2018liking\u2019,\u2018wanting\u2019, and abuse liability. Cell Mol Neurobiol. 2021;41(5):899\u2013926.","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"1445_CR28","first-page":"e15816","volume":"13","author":"A Sarangi","year":"2021","unstructured":"Sarangi A, McMahon T, Gude J. Benzodiazepine Misuse: an epidemic within a pandemic. Cureus. 2021;13(6):e15816.","journal-title":"Cureus"},{"issue":"3","key":"1445_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","volume":"6","author":"A Schmitz","year":"2016","unstructured":"Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Mental Health Clinician. 2016;6(3):120\u20136.","journal-title":"Mental Health Clinician"},{"key":"1445_CR30","doi-asserted-by":"crossref","unstructured":"Agrawal R. Careful prescribing of benzodiazepines during COVID-19 pandemic: a review. J Mental Health Clin Psychol. 2020;4(4).","DOI":"10.29245\/2578-2959\/2020\/4.1214"},{"issue":"5","key":"1445_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/ADM.0000000000000770","volume":"15","author":"E Stack","year":"2021","unstructured":"Stack E, Leichtling G, Larsen JE, Gray M, Pope J, Leahy JM, et al. The impacts of COVID-19 on mental health, substance use, and overdose concerns of people who use drugs in rural communities. J Addict Med. 2021;15(5):383\u20139.","journal-title":"J Addict Med"},{"issue":"9","key":"1445_CR32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2215-0366(20)30307-2","volume":"7","author":"C Moreno","year":"2020","unstructured":"Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care should change as a consequence of the COVID-19 pandemic. lancet psychiatry. 2020;7(9):813\u201324.","journal-title":"lancet psychiatry"},{"issue":"10","key":"1445_CR33","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/s41591-022-02028-2","volume":"28","author":"BW Penninx","year":"2022","unstructured":"Penninx BW, Benros ME, Klein RS, Vinkers CH. How COVID-19 shaped mental health: from infection to pandemic effects. Nat Med. 2022;28(10):2027\u201337.","journal-title":"Nat Med"},{"issue":"2","key":"1445_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/14659891.2021.2019331","volume":"28","author":"B Armoon","year":"2023","unstructured":"Armoon B, Higgs P, Mohammadi R. Mental health status, health service utilization, drug use behaviors associated with non-fatal overdose among people who use illicit drugs: a meta-analysis. J Subst Use. 2023;28(2):154\u201365.","journal-title":"J Subst Use"},{"key":"1445_CR35","doi-asserted-by":"crossref","unstructured":"Kesten JM, Holland A, Linton M-J, Family H, Scott J, Horwood J et al. Living under coronavirus and injecting drugs in Bristol (LUCID-B): a qualitative study of experiences of COVID-19 among people who inject drugs. Int J Drug Policy. 2021;98.","DOI":"10.1016\/j.drugpo.2021.103391"},{"issue":"4","key":"1445_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1360-0443.2007.02118.x","volume":"103","author":"KR Conner","year":"2008","unstructured":"Conner KR, Pinquart M, Duberstein PR. Meta-analysis of depression and substance use and impairment among intravenous drug users (IDUs). Addiction. 2008;103(4):524\u201334.","journal-title":"Addiction"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01445-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01445-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01445-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:54:52Z","timestamp":1781052892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01445-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01445-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the parent trial, the HERO study (ClinicalTrials.gov, NCT02824640) (Litwin et al.,\n                      \n                      ; Litwin et al.,\n                      \n                      ) was approved by an Institutional Review Board at each of the participating institutions: (i) West Virginia University; (ii) Brown University; (iii) John Hopkins; (iv) Massachusetts General Hospital; (v) Montefiore Medical Center; (vi) University of California, San Francisco; (vii) University of New Mexico; (viii) University of Washington. Written informed consent was provided by all participants of the HERO study, and the research was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Judith Feinberg reports financial support was provided by Gilead Sciences. Alain H. Litwin reports financial support was provided by Gilead Sciences. Shruti H. Mehta reports financial support was provided by Gilead Sciences. Arthur Y. Kim has served on advisory boards for Biomarin. Alain H. Litwin has served on advisory boards for Gilead Sciences and Merck Pharmaceuticals and serves on Speaker\u2019s Bureau for Gilead Sciences. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}